Healthcare

ABIVAX SA

Ticker: ABVX
Exchange: FP
Composite FIGI: BBG009CG7F64

Total Alternative Signals

2signals tracked

Weighted Sentiment

+0.43weighted index

Avg Materiality Score

3.5/ 5.0 scale

Signal Distribution

1|1|0

Alternative Data Signal Feed

Real-Time Ingestion Active

Unlock Alternative Signals Feed

Access the complete, parsed materiality analysis, long-term investment theses, and direct feed links for ABIVAX SA. Programmatic API and Webhooks available.

Earnings ReportNeutral
Filing Date: 2026-06-16

Signal Event Report - FIGI BBG009CG7F64

ABIVAX SA filed a routine foreign issuer report (6-K) with the SEC. The specific content and strategic implications of this filing are not detailed in the provided search results.

Quantitative Investment Thesis

This routine regulatory filing provides transparency but does not, on its own, alter the long-term investment thesis without further details on its content.

Materiality & Sentiment Scores
Sentiment: 0
Materiality: 3 / 5
Source Document: https://www.sec.gov/Archives/edgar/data/1956827/000119312526252360/0001193125-26-252360-index.htm
Patent FilingBullish
Filing Date: 2026-06-16

Signal Event Report - FIGI BBG009CG7F64

ABIVAX SA filed a patent application for a compound of Formula (I) and its metabolites or pharmaceutically acceptable salts for use in treating and/or preventing inflammatory diseases, disorders, or conditions.

Quantitative Investment Thesis

This patent filing strengthens ABIVAX SA's intellectual property portfolio in the inflammatory disease space, potentially securing future revenue streams and enhancing its competitive position in a significant therapeutic area.

Materiality & Sentiment Scores
Sentiment: 0.75
Materiality: 4 / 5
Source Document: https://patents.justia.com/assignee/abivax